News articles about Allergan (NYSE:AGN) have been trending somewhat negative on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Allergan earned a news sentiment score of -0.07 on Accern’s scale. Accern also assigned news stories about the company an impact score of 44.2288584409582 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s rankings:
- Zacks: Analysts Expect Allergan plc (AGN) Will Post Earnings of $4.73 Per Share (americanbankingnews.com)
- 1st trial date set in state lawsuit over opioid epidemic (marketbeat.com)
- Allergan plc Forecasted to Earn FY2018 Earnings of $15.95 Per Share (AGN) (americanbankingnews.com)
- Astound Commerce Experiences Record Year, Continues Momentum At NRF Retail’s Big Show 2018 (prweb.com)
- Concerns About Allergan’s Health Are Overblown (finance.yahoo.com)
A number of analysts have issued reports on the stock. Vetr downgraded shares of Allergan from a “buy” rating to a “hold” rating and set a $180.97 price target on the stock. in a report on Wednesday. Piper Jaffray Companies set a $227.00 price target on shares of Allergan and gave the company a “hold” rating in a report on Friday, October 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $250.00 price target (down from $277.00) on shares of Allergan in a report on Thursday, October 19th. They noted that the move was a valuation call. Leerink Swann reiterated an “outperform” rating and issued a $237.00 price target on shares of Allergan in a report on Monday, November 27th. Finally, UBS Group restated a “buy” rating and issued a $275.00 target price on shares of Allergan in a report on Tuesday, September 26th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $226.95.
Allergan (AGN) opened at $176.05 on Friday. The company has a market cap of $58,551.24, a PE ratio of -7.82, a P/E/G ratio of 1.26 and a beta of 1.11. Allergan has a fifty-two week low of $160.07 and a fifty-two week high of $256.80. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40.
Allergan (NYSE:AGN) last released its quarterly earnings data on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.06 by $0.09. The company had revenue of $4.03 billion during the quarter, compared to analysts’ expectations of $4.04 billion. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. During the same period in the previous year, the company earned $3.32 EPS. equities analysts predict that Allergan will post 16.27 earnings per share for the current fiscal year.
Allergan announced that its board has initiated a stock repurchase plan on Monday, September 25th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the company to repurchase up to 2.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.
The business also recently disclosed a quarterly dividend, which was paid on Friday, December 15th. Shareholders of record on Friday, November 17th were given a $0.70 dividend. The ex-dividend date was Thursday, November 16th. This represents a $2.80 annualized dividend and a yield of 1.59%. Allergan’s dividend payout ratio (DPR) is -12.44%.
In other Allergan news, insider William Meury sold 11,807 shares of the business’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $173.89, for a total value of $2,053,119.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher J. Coughlin acquired 10,000 shares of the stock in a transaction on Tuesday, December 5th. The stock was bought at an average cost of $163.30 per share, with a total value of $1,633,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 17,630 shares of company stock valued at $2,890,057. 0.36% of the stock is owned by corporate insiders.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.